ClinicalTrials.gg
CompletedNCT03541655Updated Jul 10, 2020

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

A Phase 2 interventional study of Bupivacaine HCl and F14 (celecoxib) in Total Knee Replacement and Postoperative Pain, sponsored by Arthritis Innovation Corporation. Completed at 3 sites in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by Arthritis Innovation Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2020.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing celecoxib in Pain, Postoperative — 2 open to participants now, 2 under way, none of them phase 3. Celecoxib · Pain, Postoperative.

Enrollment
19th of 19
20 · median 132
Started
2018
the only one that year
Phase 2
5 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
1 of 19
Arthritis Innovation Corporation

Among the 19 studies testing celecoxib in Pain, Postoperative, this one is the 19th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 2, and was the 10th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 19 studies testing celecoxib in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing celecoxib in Pain, Postoperative, or all of them as a file.
02

Study summary

The safety and activity of a single, 3.5 mL dose of F14 (celecoxib) concurrent with standard of care analgesia administered following total knee replacement will be compared to standard of care analgesia alone.

Read the detailed description

This is a randomized, single-blind, active control study in participants undergoing primary unilateral total knee replacement (TKR). Fifty (50) participants will be randomized 1:1 to receive either a single, 3.5 mL dose of F14 (celecoxib) concurrent with standard of care analgesia, or only standard of care analgesia. F14 will be administered into the joint space at the end of surgery and just prior to wound closing. Safety will be evaluated through recording of adverse events, vital signs, ECG, physical and knee-specific examinations, laboratory blood tests and standing x-rays of the TKR obtained at 3 and 12 months. Post-operative pain will be assessed using visual analog scores (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaires and the Timed Up and Go test. Concomitant medication usage including MSO4 equivalents will be monitored daily for 3 months with participant drug diaries, and at the 12-month visit. Perceived benefit of analgesia will be compared using the Overall Benefit of Analgesic Score (OBAS). The pharmacokinetic profile of celecoxib in plasma will be assessed up to 3 months. Standardized physical therapy will be implemented post-operatively. Follow-up study visits will occur at 1, 2, 3, 4 (phone) and 6 weeks, 3 and 12 months.

03

Conditions studied

  • Total Knee Replacement
  • Postoperative Pain

Keywords

  • total knee replacement
  • pain
  • celecoxib
  • intra-articular
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female indicated for primary, unilateral TKR
  • Between 45-80 years of age inclusive at the time of signing the
  • Capable of giving signed informed consent and complying with requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • (BMI) ≤ 40 kg/m²
  • Medically stable as determined by the Investigator based on pre-study medical history, physical examination, clinical laboratory tests, and 12-lead (ECG) findings
  • Absence of fixed flexion deformity exceeding 15°
  • Absence of varus or valgus deformity exceeding 15°
  • Minimum pre-operative flexion arc of 100°
  • Absence of , hyaluronic acid, rich plasma, or any other type of therapeutic injection(s) in the index knee within 3 months before scheduled surgery
  • Physical Status Classification System (ASA-PSC) score ≤ 3
  • Females of with a negative pregnancy test at screening, who agree to employ adequate measures for the full duration of the study
  • Has undergone scheduled total knee replacement surgery of the index knee, which in the opinion of the Investigator, will not affect the participant's study follow-up

Exclusion criteria

Exclusion Criteria:

  • Allergy or to active ingredient celecoxib. When an allergy to celecoxib is unknown,allergy or hypersensitivity to sulfonamide antibiotics or sulfa containing drugs
  • Active or past infection in the index knee
  • Previous total or partial knee arthroplasty in either knee within the past 6 months
  • Prior arthroscopy in the index knee in the last 6 months; knee surgery other than arthroscopy (including cruciate ligament, cartilage or osteotomy) in the index knee in the last 12 months; knee surgery in the contralateral knee in the last 12 months (excluding total or partial knee replacement)
  • Documented osteonecrosis or arthrotomy within previous 12 months
  • Prior or current presence of hardware in index knee other than screws from previous ligament repair that do not require manipulation or removal for TKR surgery
  • Other planned major surgery within 12 months of scheduled surgery
  • Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the TKR surgery emanating from other lower body joints in the ipsilateral (hip, ankle) or contralateral (hip, knee, ankle) or back (by body diagram)
  • Current or historical evidence of any disease or condition, especially cardiovascular, pulmonary or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate or affect the participant's study follow-up
  • Strong narcotic use (e.g. Oxycontin®, Vicodin®, Percocet®) before scheduled study surgery for a prolonged period exceeding 30 days within the last 2 years
  • History of alcohol abuse within previous 12 months (score of 4 on CAGE questionnaire)
  • Known or suspected history of illicit drug abuse within 1 year before randomization, or history of opioid dependence within 2 years before scheduled surgery (score exceeding 5 on DAST-10 questionnaire)
  • Participation in another clinical study involving an product (IP) or device within 30 days before screening or scheduled participation in another clinical study involving an IP or device during the course of this study
  • Use of pregabalin or gabapentin, or other drugs for neuropathic pain unless willing to discontinue at least 7 days prior to study surgery
  • Current patient-reported seizure disorder
  • Current peripheral neuropathy
  • Current depression, mood or anxiety disorder (score exceeding 14 on PHQ-9 questionnaire)
  • History of complex regional pain syndrome (CRPS)
  • Diagnosis of clinically significant liver and/or renal abnormalities within previous 2 years
  • Diagnosis of diabetes with exceeding 7
  • Current inflammatory arthritides (e.g., rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, psoriatic arthritis), or traumatic bone injuries within 12 months before scheduled surgery, but excepting clinically stable/non-active gout that does not affect the knee and does not interfere with walking
  • Treatment with , antipsychotics, anticholinergics, or anticonvulsants within 1 month of randomization
  • Diagnosis of skin disorders including psoriasis, vascular insufficiency ulcers, and chronic venous stasis
  • Participants with sleep apnea associated with a history of postoperative delirium. If symptomatic sleep apnea is currently treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP), use must be continued postoperatively
  • History of coronary or vascular stent placed within 3 months (may be extended to 1 year if medically indicated per physician discretion).
  • Participation in active or pending personal injury or workers' compensation litigation related to index knee
  • Current or planned use of medical marijuana or cannabidiol (CBD), unless willing to discontinue at least 10 days prior to study surgery and for 3 months following study surgery
  • Unwilling or unable to discontinue use of NSAIDs within 7 days of scheduled surgery and for 3 months following study surgery, including low-dose aspirin for cardiac prophylaxis
  • Has an allergy or to opioids
  • Had a in the last year, except for non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • Positive urine drug screen for disallowed medication at screening or preoperatively on day of study surgery
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Standard of care analgesia

    0.25% Bupivacaine HCl administered following total knee replacement

    Drug: Bupivacaine HCl

  • Experimental
    F14 (celecoxib)

    3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement

    Drug: Bupivacaine HCl · Drug: F14 (celecoxib)

Interventions

06

What researchers measure

Primary outcomes

  1. Peak pain intensity measured by visual analog scale (VAS)

    Time frame: At 2 weeks

  2. Area under the curve (AUC) of visual analog scale (VAS) pain intensity scores

    Time frame: Through 72 hours

  3. Summed pain intensity difference (SPID) of visual analog scale (VAS) pain intensity scores

    Time frame: Through 72 hours

  4. Functional improvement by Timed Up and Go test

    Time frame: Through 3 months

  5. Total post-surgical opioid consumption (in MSO4 equivalents)

    Time frame: Through 3 months

Secondary outcomes

  1. Peak pain intensity by visual analog score (VAS)

    Time frame: Through 12 months

  2. Pain, stiffness, and physical function by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Parts A, B, C)

    Time frame: Through 12 months

  3. Time to first rescue medication

    Time frame: Through 3 months

  4. Proportion of participants using rescue medication

    Time frame: Through 3 months

  5. Benefit of analgesia by Overall Benefit of Analgesic Score (OBAS) questionnaire

    Time frame: Through 4 weeks

  6. Celecoxib concentration in plasma

    Time frame: Through 12 months

07

Study locations

3 sites
  • Panorama Orthopedics & Spine Center
    Denver, Colorado 80401, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jun 2019, 13 months.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 13 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
May 30, 2018
StartActual
May 4, 2018
Primary completionActual
Jun 20, 2019
CompletionActual
Mar 30, 2020
Results delay requested
Jul 7, 2020
Last update
Jul 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03541655
Lead sponsor
Arthritis Innovation Corporation
Responsible party
Sponsor
First posted
May 30, 2018
Start date
May 4, 2018
Primary completion
Jun 20, 2019
Completion
Mar 30, 2020
Last update
Jul 10, 2020

Study contacts

Jared Foran, MD
principal investigator · Panorama Orthopedics & Spine Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion